Framing Short- & Long-Term Policy Pathways to Sustain Cell & Gene Therapy Adoption & System Level Affordability
- Drawing on early lessons from establishing DRG 18 to clarify how initial reimbursement structures have supported inpatient sustainability while exposing unresolved gaps for future cell and gene therapy volumes
- Mapping the core components of today’s reimbursement ecosystem to highlight why cell and gene therapies strain traditional frameworks and which stakeholder questions must be answered to ensure long term policy viability
- Integrating short term policy recommendations with forward looking considerations to outline what must be addressed now to sustain Medicare and Medicaid affordability as cell and gene therapy pipelines expand